Glaukos Corp. (GKOS)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$177.47-1.60%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · GKOS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 30.3% |
| Our one-year growth estimate | diamond | 27.4% |
Growth built into the price is above our model estimate.
The price assumes 2.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
GKOS — earnings miss
Dated 2026-02-17
Results of Operations and Financial Condition. On February 17, 2026, Glaukos Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information contained in this
Why it matters: Positive cash flow would show better financial health and efficiency.
Supportive ifCash flow from operations turns positive and exceeds $10 million.
Worry ifCash flow from operations is still negative.
Why it matters: A decline in sector revenue growth could signal broader challenges. This may impact Glaukos' performance.
Worry ifSector revenue growth drops below its median for the first time in 3 years.
Less concerning ifSector revenue growth remains above its median.
Why it matters: Improving gross profit shows better cost management and product demand. This can support stock performance.
Supportive ifGross profit margin improves by more than 5% in the next quarter.
Worry ifGross profit margin declines or remains flat.
Why it matters: Strong adoption of iDose TR would confirm the success of Glaukos' new treatment paradigm.
Supportive ifiDose TR adoption shows that over 70% of patients use the product well.
Worry ifAdoption metrics show less than 50% of patients use the product successfully.
Why it matters: New iDose TR could increase sales in the glaucoma market.
Supportive ifPositive results from the ongoing Phase 3b study of iDose TR.
Worry ifNegative trial results or delays in the iDose TR clinical program.
Why it matters: The earnings report will show if revenue growth is stable or declining. This is key for investors.
Watch forRevenue growth is above the median for the sector. This shows strong performance.
Also watch forRevenue growth drops below the median for the sector, signaling potential issues.
Why it matters: An increase in revenue guidance would show strong growth momentum for Glaukos.
Supportive ifManagement raises the revenue forecast for 2026 to more than $700 million.
Worry ifManagement keeps or lowers the revenue forecast to less than $680 million.
Why it matters: Selling these products well is important for Glaukos's growth.
Supportive ifManagement reports strong sales growth from iDose TR and Epioxa in Q3.
Worry ifSales from iDose TR and Epioxa remain flat or decline in Q3.
Why it matters: Better gross margins show improved cost control and product profits.
Supportive ifGross margin exceeds 85% in Q3.
Worry ifGross margin falls below 82% in Q3.
Why it matters: Having positive cash flow is important for financial health and growth.
Supportive ifCash flow from operations turns positive in Q3.
Worry ifCash flow from operations remains negative in Q3.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$154 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $399 loss on $10,000 · 4.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,839 loss on $10,000 · 28.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.